These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34931119)
21. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962 [TBL] [Abstract][Full Text] [Related]
22. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. Chakraborty S Biochem Biophys Res Commun; 2021 Jan; 538():97-103. PubMed ID: 33602511 [TBL] [Abstract][Full Text] [Related]
23. Adsorption of SARS-CoV-2 Spike (N501Y) RBD to Human Angiotensin-Converting Enzyme 2 at a Lipid/Water Interface. Rozak H; Nihonyanagi S; Myalitsin A; Roy S; Ahmed M; Tahara T; Rzeznicka II J Phys Chem B; 2023 May; 127(20):4406-4414. PubMed ID: 37171105 [TBL] [Abstract][Full Text] [Related]
24. Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability. Verma J; Subbarao N Virology; 2021 Sep; 561():107-116. PubMed ID: 34217923 [TBL] [Abstract][Full Text] [Related]
25. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Lata S; Akif M J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980 [TBL] [Abstract][Full Text] [Related]
26. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558 [TBL] [Abstract][Full Text] [Related]
27. ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner. Isobe A; Arai Y; Kuroda D; Okumura N; Ono T; Ushiba S; Nakakita SI; Daidoji T; Suzuki Y; Nakaya T; Matsumoto K; Watanabe Y Commun Biol; 2022 Nov; 5(1):1188. PubMed ID: 36335195 [TBL] [Abstract][Full Text] [Related]
28. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095 [TBL] [Abstract][Full Text] [Related]
29. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
30. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. Hussain M; Jabeen N; Raza F; Shabbir S; Baig AA; Amanullah A; Aziz B J Med Virol; 2020 Sep; 92(9):1580-1586. PubMed ID: 32249956 [TBL] [Abstract][Full Text] [Related]
31. Structure-based virtual screening and molecular docking of drugs against the SARS-CoV-2 spike protein-ACE2 receptor complex. Ahmad I; Ali M; Ali R; Nawaz N; G Patching S Pak J Pharm Sci; 2022 Nov; 35(6):1531-1538. PubMed ID: 36789812 [TBL] [Abstract][Full Text] [Related]
32. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530 [TBL] [Abstract][Full Text] [Related]
34. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098 [TBL] [Abstract][Full Text] [Related]
35. Phytocompounds of Rolta R; Salaria D; Sharma P; Sharma B; Kumar V; Rathi B; Verma M; Sourirajan A; Baumler DJ; Dev K Curr Pharmacol Rep; 2021; 7(4):135-149. PubMed ID: 34306988 [TBL] [Abstract][Full Text] [Related]
36. Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2. Zhang ZB; Xia YL; Shen JX; Du WW; Fu YX; Liu SQ Cells; 2022 Apr; 11(8):. PubMed ID: 35455955 [TBL] [Abstract][Full Text] [Related]
37. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663 [TBL] [Abstract][Full Text] [Related]
38. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993 [TBL] [Abstract][Full Text] [Related]
39. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related]
40. Corilagin and 1,3,6-Tri- Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]